EMA and HMA Have Published Their Joint Strategy for the Next Five Years

EMA and the Heads of Medicines Agencies (HMA) have published their joint strategy for the next five years, following its recent adoption by the HMA and EMA Management Board.

The strategy details how the European medicines regulatory network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges posed by ever-accelerating developments in science, medicine, digital technologies, globalisation as well as emerging health threats, such as the COVID-19 pandemic.

“The COVID-19 pandemic has highlighted the pivotal role of medicine regulation for the protection of public health,” said Emer Cooke, EMA’s Executive Director. “Lack of availability of medicines, either because they are not marketed or due to supply disruptions, has shown to pose serious threats to patient and animal health, animal disease control programs and sustainable livestock production. This strategy ensures that we join forces across the EU to effect tangible improvements for citizens.”

The European medicines agencies network strategy to 2025 outlines six priority areas for the network:

• the availability and accessibility of medicines;
• data analytics, digital tools and digital transformation;
  innovation;
• antimicrobial resistance and other emerging health threats;
  supply chain challenges; and
• the sustainability of the network and operational excellence.

Èñòî÷íèê